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October 20101122 Abstractsisolated to calf veins, and 9 (20%) were coexistent in calf and proximal veins.
Of the isolated calf DVTs, only two progressed to the popliteal vein or
proximal on follow-up. No examined risk factor predicted DVT. Mechanical
prophylaxis was uniformly used, but chemical prophylaxis varied based on
surgeon preference. DVT developed in 19.3% (28 of 145) of patients
receiving prophylactic medication (unfractionated heparin or low-molecu-
lar-weight heparin) and in 41.4% (12 of 29) receiving no medication (P 
.001).
Conclusions: Despite application of mechanical and chemical DVT
prophylaxis, we found a 23% incidence of DVT in hospitalized, nonambu-
latory, neurosurgical patients. No patients with isolated calf DVT had an
embolic complication, and only 11.7% progressed proximally. Although
chemical prophylaxis reduced DVT risk, no factor was sufficiently predictive
to exclude patients from screening. These data substantiate the importancecells were serum starved for 24 hours to synchronize them to the G0 phase.
HCASMCs were then stimulated into the cell cycle and harvested for totalContinuous Inhibition of Poly-ADP Ribose Polymerase Improves
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Introduction and objectives: Poly (ADP)-ribose polymerase (PARP)
inhibition during the acute phase of limb ischemia/reperfusion injury (IR)
has been shown to be protective; however, elevated levels of PARP activity
persists during the chronic phase of reperfusion. The primary goal of these
experiments was to determine whether ongoing post hoc PARP inhibition
potentiated muscle regeneration and functional recovery after IR.
Methods: C57BL6/J mice were subjected to 1.5 hours of unilateral
hind limb ischemia, followed by 2 weeks of reperfusion. During ischemia,of VDUS screening and support revising our protocol to evaluate femoral
and popliteal veins only.
mice were treated with a PARP inhibitor PJ34 (PJ, n 12) by implantation
of a continuous slow-release pellet (10 mg/kg/d for 14 days), or placebo
Table. Outcomes of PARP inhibition
Variable PJ34 Control P
Ambulation score (1  normal, 4  dragging) 1.7 2.8 .001
Peak force muscle contracture, grams 68.1 62.1 .03
PAR expression
Densitometry value 14,288  1276 26,839  5830 .022
Percent immature fibers 8.32  4.70 77.5  8.2 .001
ATP
Tissue level, nmol/mg 5.93  0.27 3.73  0.50 .001
Myogenin
Densitometry value 45,285  6,340 83,531  22,507 .051
Perfusion ratio (injured/noninjured limb) 0.959  0.048 0.921  0.062 .636pellet (control, n  12). Hind limb function was analyzed with ambula-
tion scoring scale and muscle contractility using direct muscle stimula-
tion. Muscle regeneration and PARP activity were assessed by immuno-
blotting for myogenin, a transcription factor associated with myofibers
differentiation, and poly ADP-ribose (PAR). ATP levels were measured
with chemiluminescence. Immature muscle fibers were counted micro-
scopically. Hind limb perfusion ratios were measured by laser-Doppler
imaging.
Results: Inhibition of PARP was confirmed by decreased PAR expres-
sion in PJ mice (see Table). Ambulation scores and muscle contractility were
improved in PJ mice. This improved functional status correlated with a
higher number of mature muscle fibers and preservation of ATP. Myogenin
expression was decreased in PJ mice, but was not significant. These changes
were not due to differences in perfusion based on laser-Doppler imaging
ratios.
Conclusions: Continuous PARP inhibition significantly improves
hind limb function after IR. This improved function is associated with
increased numbers of mature fibers and improved levels of high-energy
phosphate in the muscle. PJ34 may prove to be a pharmacologic treat-
ment useful in ameliorating the effects of reperfusion injury after isch-
emia insult.
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Introduction and objectives: The myristoylated alanine-rich C-kinase
substrate (MARCKS), a major protein kinase C substrate, is upregulated in
intimal hyperplasia (IH), yet its signaling pathway remains undetermined.
Through inhibition of vascular smooth muscle cell (VSMC) migration and
proliferation, p27kip1, a cyclin-dependent kinase inhibitor, regulates IH. We
have previously demonstrated MARCKS siRNA-mediated knockdown de-
creases VSMC migration and proliferation and increases p27kip1 expression.
The MAP kinases SAP/JNK, p38, and ERK1/2 are important regulators of
the cell cycle and interact with p27kip1. The goal of the present study was to
monitor the protein expression of p38, ERK1/2, and SAP-JNK in the
setting of MARCKS knockdown.
Methods: Human coronary artery smooth muscle cells (HCASMC)
were transfected with 50 nm control, or MARCKS siRNA, or vehicle. Theprotein extraction along different points of the cell cycle (0 and 30 minutes,
18 and 24 hours). Western blot analysis was performed to monitor the
protein expression of MARCKS, p27kip1, p38, ERK1/2, and SAP/JNK.
Results: All of the following results are presented as percent change in
protein expression in MARCKS siRNA-treated HCASMCs compared with
control siRNA-treated HCASMCs. MARCKS siRNA treatment resulted in
(1) 40% to 75% decrease in MARCKS expression at all different time points,
(2) a 30% increase in p27kip1 at all different time points, (3) no change in p38
expression at 0 and 30 minutes and a 25% increase at later time points, (4) no
change in SAP-JNK expression at 0 and 30 minutes and a 30% to 78%
increase at later time points, (5) no change in ERK1/2 expression at all
different time points.
Conclusions: The results of this study shed light on a possible IH
signaling pathway mediated by MARCKS through p27kip1, p38, and SAP-
JNK MAP kinase regulation.
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Introduction and objectives: Conventional in vitro flow models of
vein graft adaptation have not previously characterized the vessels according
to their markers of specificity. In particular, it is not known whether in vitro
models of vein graft adaptation mimic physiologically reduced expression of
the venous determinant ephrin-B4 or whether they stimulate expression of
the arterial determinant ephrin-B2.
Methods: Saphenous vein remnants were taken from the operating
room and immediately placed in a flow circuit. Medium was circulated at 20
dyne/cm2 for 24 hours, and then specimens were analyzed with H&E, von
Giessen, and TUNEL staining. Protein was analyzed using Western blot-
ting, and was RNA analyzed using qPCR.
Results: After 24 hours of arterial flow in vitro, saphenous veins were
viable, with no detectable induction of either activated caspase-3 or PARP
cleavage (n  6); TUNEL staining showed no increase over baseline.
Endothelial cells were identified on the luminal surface, and PECAM was
present both initially and after 24 hours of flow. Ephrin-B4 expression was
diminished (n  6, P  .04), and there was no induction of ephrin-B2
expression (n 6, P .001). Expression of osteopontin (n 7, P .001),
a marker of vein graft adaptation, was increased.
Conclusions: This novel in vitro flow model preserves human saphe-
nous vein viability for at least 24 hours, including vessel endothelium. When
exposed to the bioreactor environment, markers of venous and arterial
